BioMedNewsBreaks

ThursdayFeb 10, 2022 12:12 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company's IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product…

Continue Reading

ThursdayFeb 10, 2022 12:03 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the call will be held Feb. 15, 2021, at 2 p.m. ET. Those interested can dial +1 (855) 605-1745 (United States and Canada) or +1 (914) 987-7959 (international) using conference ID 8645175. In addition, the company’s full financial statements and related MD&A along with a replay of the…

Continue Reading

TuesdayFeb 08, 2022 1:37 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs for approved patients who have not responded to other treatment options. Available to Mydecine through its exclusive agreement with Applied Pharmaceutical Innovation (“API”), the licensed dealer facility contains a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada. With the…

Continue Reading

ThursdayFeb 03, 2022 3:36 pm

BioMedNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Miboko Launch Leveraging ‘Most Reliable Gateway Toward Wider Adoption of Preventative Health Maintenance Practices’

Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or insulin resistance. The device is linked to an AI mobile application, which seeks to provide users with personalized information by tracking their metabolism. Users will be able to find out how well their body responds to sugar through their metabolic health score. Nemaura Medical believes…

Continue Reading

ThursdayFeb 03, 2022 11:30 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and educational organization, MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use. “We are thrilled to welcome…

Continue Reading

WednesdayFeb 02, 2022 2:56 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a…

Continue Reading

WednesdayFeb 02, 2022 2:45 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (“GBM”). The approval also partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. GBM is one of the most aggressive, deadly and treatment-resistant cancers that form in the brain. “So far, the company has selected tens of clinical sites across the…

Continue Reading

TuesdayFeb 01, 2022 12:12 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program. Principal Investigator Dr. Matthew Johnson, Ph.D., professor of psychiatry and behavioral sciences at Johns Hopkins University, will lead the study that will assess the safety and efficacy of psilocybin-assisted…

Continue Reading

MondayJan 31, 2022 3:32 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing sector rife with opportunity. “Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (‘JHU’) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment… In 2022, Johnson…

Continue Reading

MondayJan 31, 2022 1:50 pm

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) Partners with Renowned Expert to Discuss Alcohol Use Disorder and Trauma at Upcoming Virtual Event

Clearmind Medicine (CSE: CMND) (OTC: CMNDF) (FSE: CWY0) is a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems. The company has announced that, as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté to discuss alcohol use disorder and how Clearmind’s candidate treatment may create a clear path to dealing with trauma. The special virtual event, slated to take place starting at 12 p.m. ET on Feb. 3, 2022, is open and free to all, with registration required. Renowned speaker and bestselling author Dr.…

Continue Reading